Xolair 150mg Injection

Xolair 150mg Injection contains the active ingredient omalizumab, which is a monoclonal antibody. It is designed to target and bind to immunoglobulin E (IgE), a type of antibody involved in allergic reactions. By binding to IgE, Xolair inhibits its ability to trigger allergic responses, thereby reducing the symptoms associated with allergic conditions.

Active Ingredient:

• Omalizumab: Omalizumab is a recombinant DNA-derived humanized monoclonal antibody that selectively binds to IgE, thereby preventing it from binding to its receptors on immune cells and triggering allergic reactions.

Mechanism of Action:

Omalizumab binds to the Fc portion of IgE antibodies, thereby preventing the interaction of IgE with its receptors on mast cells and basophils. This inhibits the release of allergic mediators such as histamine and leukotrienes, leading to a reduction in allergic symptoms.

Uses:

Xolair 150mg injection is indicated for the treatment of allergic conditions, including:

• Moderate to severe persistent allergic asthma in patients who have a positive skin test or in vitro reactivity to a perennial allergen and whose symptoms are inadequately controlled with inhaled corticosteroids.
• Chronic idiopathic urticaria (CIU) in patients aged 12 years and older who remain symptomatic despite H1 antihistamine treatment.

Dosage and Administration:

The dosage of Xolair 150mg injection is based on the patient’s body weight and serum total IgE level. It is administered subcutaneously every 2 to 4 weeks by a healthcare professional. The injection should be given in the upper arm, thigh, or abdomen, and the injection site should be rotated with each injection.

Side Effects:

Common side effects of Xolair 150mg injection may include:

• Injection site reactions (e.g., pain, erythema, swelling)
• Headache
• Fatigue
• Dizziness
• Upper respiratory tract infection
• Viral infections
• Injection site bruising
• Throat pain
• Nausea

Precautions:

• Xolair should be administered under the supervision of a healthcare professional experienced in the diagnosis and treatment of asthma or chronic urticaria.
• Patients should be monitored for signs of anaphylaxis or hypersensitivity reactions during and after administration of Xolair.
• Xolair should not be used to treat acute asthma exacerbations or acute episodes of urticaria.
• Patients should continue to use their prescribed asthma medications or antihistamines as directed by their healthcare provider, even if they are receiving Xolair treatment.

Conclusion:

Xolair 150mg injection is a monoclonal antibody therapy used for the treatment of allergic asthma and chronic idiopathic urticaria. By targeting IgE, Xolair helps to reduce allergic symptoms and improve disease control in patients with these conditions.